Steven M Devine MD

Steven M Devine MD
ProfessorCollege of Medicinedevine.54@osu.edu
B316 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-5655Fax: 614-293-6690
  • Experimental Therapeutics

Current Publications

  • Yu JGenetic Modification of T Cells Redirected towards CS1 Enhances Eradication of Myeloma Cells.Clin Cancer Res 3/27/2014
  • Yu JFLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome.Biol Blood Marrow Transplant 20 309-13 3/1/2014
  • Devine SMGraft-versus-host disease: why have we not made more progress?Curr Opin Hematol 21 141-7 3/1/2014
  • Blum KAComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.Cancer 2/27/2014
  • Devine SMReprint of: Re-Examining the Role of High-Dose Chemotherapy in the Treatment of Light Chain Amyloidosis.Biol Blood Marrow Transplant 20 S2-S7 2/1/2014
  • Devine SMRe-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.Biol Blood Marrow Transplant 20 14-9 1/1/2014
  • Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LIDisabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.J Clin Oncol 31 4199-206 11/20/2013
  • Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci GPhase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.Leuk Lymphoma 11/1/2013
  • Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti DPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest 123(10) 4144-57 10/1/2013
  • Bredeson C, Lerademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MCProspective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Blood in press 9/30/2013
  • Chu J, Deng Y, Benson DM Jr, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu JCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Leukemia in press 9/26/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48(9) 1212-7 9/1/2013
  • Jones J, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, , McGourty J, Moledor M, Lowe R, Setter B, , Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy NGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs 5(5) 723-35 9/1/2013
  • Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum WPhase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Leuk Lymphoma in press 8/16/2013
  • Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YAEarly versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Leuk Lymphoma 54(8) 1658-64 8/1/2013
  • Phelps MAStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Clin Pharmacokinet 52(8) 705-12 8/1/2013
  • He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister C, He X, Ghoshal K, Devine SM, Caligiuri MA, Yu JMicroRNAs activate natural killer cells through Toll-like receptor signaling.Blood 121(23) 4663-71 6/6/2013
  • Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin REWho is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?Blood 121(13) 2567-73 3/28/2013
  • Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LAComplex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.Br J Haematol 159(1) 82-7 10/1/2012
  • Devine SMToward a more rational policy for autologous hematopoietic stem cell mobilization.Biol Blood Marrow Transplant 18(10) 1468-70 10/1/2012
  • Bruce JT, Tran JM, Phillips G, Elder P, Mastronarde JG, Devine SM, Hofmeister CC, Wood KLChemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.Clin Lymphoma Myeloma Leuk 12(5) 325-9 10/1/2012
  • Tran J, Norder E, Diaz P, Phillips GS, Elder P, Devine SM, Wood KLPulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.Biol Blood Marrow Transplant 18(8) 1250-4 8/1/2012
  • Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci GClinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Blood 119(25) 6025-31 6/21/2012
  • Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri MA, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon RRegulation of acute graft-versus-host disease by microRNA-155.Blood 119(20) 4786-97 5/17/2012
  • McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker CLenalidomide after stem-cell transplantation for multiple myeloma.N Engl J Med 366(19) 1770-81 5/10/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu